A novel molecular subtype of hepatocellular carcinoma

based on the tumor purity and tumor

microenvironment-related polygenic risk scores

Yan Lin^{1†}, Rong Liang^{1†}, Xing Gao¹, Ziqin He¹, Lu Lu¹, Min Luo¹, Qian Li¹, 1

Xiaobo Wang², Yongqiang Li¹, Guobin Wu^{2*}, Xiaoling Luo^{3*}, Jiazhou Ye^{2*} 2

- 3 ¹ Department of Medical Oncology, Guangxi Medical University Cancer Hospital,
- 4 Nanning, Guangxi, People's Republic of China.
- 5 ² Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital,
- Nanning, Guangxi, People's Republic of China. 6
- 7 ³ Department of Experimental Research, Guangxi Medical University Cancer Hospital,
- 8 Nanning, Guangxi, People's Republic of China.
- 9 [†]These authors have contributed equally to this work and share first authorship

* Correspondence: 10

- 11 Jiazhou Ye
- yejiazhou@gxmu.edu.cn 12
- 13 Xiaoling Luo
- 14 luoxiaoling@gxmu.edu.cn
- Guobin Wu 15
- 16 wuguobin@gxmu.edu.cn

17 Keywords: Hepatocellular carcinoma, molecular classification, tumor

- microenvironment, immunotherapy, precision medicine. 18
- 19 Abstract
- 20 Purpose The purpose of the present study was to use malignant cell-related and tumor
- 21 microenvironment (TME)-related molecules to develop a novel molecular subtype of
- 22 hepatocellular carcinoma (HCC).
- 23 Methods The tumor purity (TP)-related and TME-related genes were identified and
- 24 separately used to construct the TP-related and TME-related polygenic risk score
- 25 (PRS). According to the two PRSs, we developed the TP-TME risk classification
- 26 which was validated in two external data sets from The Cancer Genome Atlas
- 27 Program and International Cancer Genome Consortium database. We also performed
- 28 functional enrichment and drug repositioning analysis to reveal the potential

29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Diological heterogeneity among different subtypes.

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 30 **Results** The three TP-TME risk subtypes of HCC had significantly different
- 31 prognosis and biological characteristics. The TP-TME low risk subtype had the best
- 32 prognosis and was characterized by well-differentiated, the TP-TME high risk
- 33 subtype had the worst prognosis and was characterized by aberrant activation of
- 34 TGF β and WNT pathways, and the TP-TME high risk subtype had the moderate
- 35 prognosis and was characterized by exhibited activated MYC targets and
- 36 proliferation-related gene sets. These three TP-TME risk subtypes may respond
- 37 differently to immunotherapy (e.g., immune checkpoint inhibitors and chimeric
- 38 antigen receptor-modified T cells) or other drug therapies.
- 39 Conclusion By combining the TP-related PRS and TME-related PRS, we proposed
- 40 and validated the TP-TME risk subtyping system to divide patients with HCC into
- 41 three subtypes with distinct biological characteristics and prognoses. These findings
- 42 highlight the significant clinical implications of the TP-TME risk subtyping system
- 43 and provide potential personalized immunotherapy strategies for HCC.

44 **INTRODUCTION**

- 45 Hepatocellular carcinoma (HCC) is the most common primary liver cancer and ranks
- 46 as the sixth most common neoplasm and the third leading cause of cancer death.(1)
- 47 The development of HCC is a complex multistep process that involves the
- 48 accumulation of somatic genomic alterations in driver genes in addition to epigenetic
- 49 modifications, which lead to its huge molecular heterogeneity.(2) The current systems
- 50 for HCC staging or subtyping are mainly according to radiologic, serologic, and
- 51 pathologic-based tumor burden evaluations.(3) However, a previous study(4)
- 52 indicated that HCCs at the same stage have diverse molecular characteristics. Thus, it
- 53 is imperative to propose more precise subtyping system for predicting prognosis and
- 54 treatment effects. Given the advances in sequencing technology, several molecular
- subtyping systems were developed according to multi-omics features of HCC,
- 56 nevertheless, the differences of the previous studies in technological platforms,
- 57 preparation, and processing of samples make it difficult to explore a common method
- 58 for typing HCC.(5) Thus, none of these molecular classifications so far are
- 59 recommended to predict disease progression or prognosis.(6)
- 60 In addition, heterogeneous tumor microenvironment (TME) in HCC is also a crucial
- 61 part of tumor heterogeneity. It is now increasingly accepted that tumor cells are not
- 62 working alone but interact closely with the TME.(7) The heterogeneous TME affects
- 63 tumor response to various treatments.(8) Targeting the TME was proposed as a
- 64 strategy for removing obstruction to anticancer immune responses and
- 65 immunotherapy.(8) Intriguingly, few molecular classifications of HCC have so far
- taken into account both the related molecules of malignant cells and TME. Thus, in
- 67 the present study, we tried to develop a novel molecular classification for HCC

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 68 according to the expression patterns of malignant cell (tumor purity)- and
- 69 TME-related genes. These unique risk factor patterns may provide a new frame to
- 70 study cancer heterogeneity.

71 MATERIALS AND METHODS

72 Data Processing

- 73 We screened the HCCDB database (<u>http://lifeome.net/database/hccdb/home.html</u>)(9)
- to find the candidate data sets. The inclusion criteria were as follows: 1) the data set
- r5 included both gene expression profiles and prognosis of patients with HCC, 2) the
- number of patients with a survival of more than 30 days should be more than 100, 3)
- and the gene expression profile of the dataset should contain more than 10,000 genes.
- According to the inclusion criteria, three data sets (GSE14520_GPL3921,
- 79 TCGA-LIHC, and LIRI-JP) were selected and downloaded from HCCDB database
- for our analyses. Data set GSE14520_GPL3921(10) included the gene expression
- 81 profiles based on the GPL3921 platform containing 225 HCC and 220 tumor-adjacent
- 82 liver tissue samples were utilized to develop our subtyping systems. TCGA-LIHC
- 83 data set containing RNA sequencing (RNA-seq) data and clinical information of 356
- 84 HCC belongs to The Cancer Genome Atlas Program (<u>https://www.cancer.gov/tcga</u>),
- 85 and LIRI-JP data set containing RNA-seq data and clinical information of 212 HCC
- 86 from JP Project from International Cancer Genome Consortium (<u>https://dcc.icgc.org/</u>)
- 87 were used to validated the subtyping systems. The workflow of the present was shown
- 88 in **Figure 1**.

89 Calculation of tumor purity and TME score and identification of differentially 90 expressed genes (DEGs) in GSE14520 GPL3921

- 91 The gene expression profiles of GSE14520_GPL3921 were firstly utilized to calculate
- 92 tumor purity (TP) using the ESTIMATE package.(11) Then, GSE14520_GPL3921
- 93 was also used to calculate the TME score using the xCell tools
- 94 (<u>https://xcell.ucsf.edu/</u>)(12) with the xCell gene signature. The DEGs in HCC
- 95 compared to tumor-adjacent liver tissue were identified using limma package.(13)
- 96 Genes with fold changes > 1.5 and P (adjusted by false discovery rate) value < 0.05
- 97 were considered significant.

98 Normality test and correlation analysis

- 99 The tumor purity and TME score were separately performed Shapiro-Wilk test.
- 100 Spearman or Pearson correlation analyses were performed to calculate the correlation
- 101 between DEGs and TP and TME score. A DEG showed a positive correlation with TP
- 102 and a negative correlation with TME score was considered a TP-related gene, while a
- 103 DEG showed a negative correlation with TP and a positive correlation with TME

Novel Molecular Classification of HCC

- score was considered a TME-related gene. In addition, the TME-related genes do not 104
- include mark genes of TME cells in xCell signature. 105

106 Protein-protein interaction (PPI) networks

- The PPI networks of TP-related and TME-related genes were obtained from STRING 107
- database (version 11.5)(14) to preliminarily reveal the crosstalks between the tumor 108
- cells and TME. The interactions with the high confidence (>0.7) were included in our 109
- 110 present study and visualized using the Cytoscape software (version 3.8.0).(15)

111 Development of the TP- and TME-related gene-based polygenic risk scores

- Firstly, for developing the TP-related polygenic risk score (PRS), the overall survival 112
- 113 (OS)-associated TP-related genes were identified using univariate Cox regression
- analysis. Secondly, the expression profiles of the OS-associated TP-related genes 114
- 115 were used to carry out the least absolute shrinkage and selection operator (LASSO)
- 116 Cox regression model analysis with leave-one-out cross validation using glmnet
- package.(16) The genes with non-zero coefficient were considered the optimal 117
- 118 features and subjected to multivariate Cox regression and stepwise regression analysis.
- Then the TP-related PRS was developed as the formula: TP-related PRS = Σ 119
- 120 (Expression_i * Coefficient_i). Where the "Coefficient" and "Expression" represent the risk
- 121 coefficient and expression of each gene in the multivariate cox regression and
- 122 stepwise regression analysis, respectively. The TME-related PRS was also developed
- according to the same method as above. 123

124 The TP-TME subtyping of HCC

- The optimal cutoffs of the TP-related and TME-related PRS were identified using the 125
- surv cutpoint function from survminer package 126
- 127 (https://CRAN.R-project.org/package=survminer) to separately divide patients into
- 128 high and low TP- and TME-related PRS groups. Each individual got a TP- and a
- 129 TME-related PRS level, and we developed the TP-TME subtype according to the TP-
- 130 and TME-related PRS levels. Patients possessing high TP- and TME-related PRS
- 131 were considered as the high-risk subtype, those possessing low TP- and TME-related
- 132 PRS were considered the low-risk subtype, and the remaining patients possessing a
- 133 high TP-related and low TME-related PRS or a low TP-related and high TME-related
- PRS were considered the intermediate-risk subtype. 134

135 Gene set enrichment analysis (GSEA)

- 136 In order to preliminarily reveal the biological characteristics of these three risk
- subtypes, we performed GSEA(17, 18) in the GSE14520 GPL3921 data set using the 137
- GSEA java software (http://www.gsea-msigdb.org/gsea/index.jsp). 138 Hallmark gene

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 139 sets and canonical pathway gene sets derived from the Kyoto Encyclopedia of Genes
- 140 and Genomes (KEGG) pathway database were download from The Molecular
- 141 Signatures Database (MSigDB)(18-20) and used as the reference gene sets. The
- 142 threshold was set to nominal P (NOM P) value < 0.05 or FDR q value < 0.25.

143 Analyses of gene mutation and stemness score

- 144 Gene mutation data of TCGA-LIHC data set were extracted from mutation annotation
- 145 format (MAF) files using the *GDCquery_Maf* function in the "TCGAbiolinks"
- 146 package.(21) Gene mutation frequencies of each risk subtype were visualized as a
- 147 waterfall plot using the *oncoplot* function in the "TCGAbiolinks" package. The tumor
- 148 mutational burden (TMB) of each sample was obtained from a previous study.(22)
- 149 The stemness score(23) was calculated for each individual in the TCGA-LIHC data
- 150 set using *TCGAanalyze_Stemness* function in the "TCGAbiolinks" package.

151 **Prediction of efficacy of therapy**

- 152 Immunotherapy has achieved tremendous successes in treatment of various
- 153 cancers,(24) including HCC.(25) Treatment of immune checkpoint inhibitors (ICIs)
- 154 and chimeric antigen receptor-modified T cell (CAR-T) were currently the two most
- 155 widely studied immunotherapies. The expression of immune checkpoints was
- associated with the efficacy of ICIs.(26) The therapeutic effect of CAR-T cells is
- related to the expression of target genes in the tumor cells. For the TP-TME risk
- 158 subtypes, we compared the expression levels of two immune checkpoints (PDL1 and
- 159 CTLA4) and five antigens (CD133, EPCAM, GCP3, MSLN, and MUC1)(27) to
- 160 predict the potential response to these treatments. In addition, we performed drug
- 161 repositioning analysis for the high-risk subtype using the PATHOME-Drug
- 162 (<u>http://statgen.snu.ac.kr/software/pathome/</u>) web tools.

163 Statistical analysis

- 164 In our present study, unless otherwise stated, all these analyses were performed in R
- 165 (version 4.0.2). We identified DEGs using unpaired t-tests provided by limma
- 166 package. Shapiro-Wilk test was used for the nrmality test. Time-dependent receiver
- 167 operating characteristic curve (tROC) analysis was carried out using the tROC
- 168 package.(28) Kaplan–Meier survival curves for overall survival (OS) and progression
- 169 free survival (PFS) were compared in different subtypes using the log-rank method in
- 170 the "survival" package (<u>https://CRAN.R-project.org/package=survival</u>) and
- 171 "survminer" package (<u>https://CRAN.R-project.org/package=survminer</u>). Intergroup
- 172 differences in continuous variables were assessed for significance using Wilcoxon,
- 173 Kruskal–Wallis, or unpaired t-tests. All tests were two-sided and unless otherwise
- 174 stated, we set P value < 0.05 to be statistically significant.

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

175 **RESULTS**

176 The biological functions and interactions of tumor purity (TP)-related and **TME-related** genes 177

We identified a total of 2263 DEGs in HCC compared to tumor-adjacent liver tissue 178 (Figure 2A). Both the TP and TME score showed non-normal distribution with 179 Shapiro-Wilk P < 0.001. A total of 451 TP-related and 121 TME-related genes were 180 identified by Spearman correlation analysis, and the bidirectional hierarchical 181 182 clustering showed the expression patterns of them could basically distinguish HCC 183 and tumor-adjacent liver tissue (Figure 2B). Unsurprisingly, the TP-related genes are mainly involved in cancer-related gene ontology terms or pathways (Figure 2C), such 184 as cell cycle and mismatch repair; while the TME-related genes are mainly involved 185 in immune system (Figure 2D). The PPI networks of the TP-related and TME-related 186 genes contain 342 nodes and 1177 edges (Figure 2E). Red indicates upregulated and 187 blue indicates downregulated in the metastasis group, while circular nodes represent 188 189 the TP-related genes and rhombic nodes represent the TME-related genes.

190 The TP-TME risk subtyping is a robust prognosis prediction system

191 Fifty TP-related genes were identified as OS-associated genes, twenty-two of them 192 possess non-zero coefficient (Figure 3A), and eleven genes (ALG6, ATP5MF, CNIH4, 193 ESM1, HEY1, LANCL1, P2RX4, PEX11B, POP7, RCN2, and XPO1) were used to generate the TP-related polygenic risk score (PRS) (Supplementary Table 1). The 194 195 TP-related PRS was significantly associated with overall survival (OS) with P <0.0001, Hazard Ratio (HR) = 2.718 (95% CI for HR = 2.147-3.442) and the area under 196 197 curve (AUC) of tROC analysis was stably around 0.8 (Figure 3B). The HCC patients 198 with high TP-related PRS showed shorter OS than those with low TP-related PRS (P < 0.0001) (Figure 3C). In the TME-related genes, twelve genes were identified as 199 OS-associated genes, ten of them possess non-zero coefficient (Figure 3D), and seven 200 201 genes (ALDH1B1, CTSC, GUCY1A1, MRC1, SPRY2, TARP, and TRIM22) were used 202 to generate the TME-related PRS (Supplementary Table 2). The TME-related PRS 203 was also significantly associated with OS with P < 0.0001, Hazard Ratio (HR) = 2.718 (95% CI for HR = 1.978-3.735) and the AUC of tROC analysis was 0.7-0.8204 205 (Figure 3E). The HCC patients with high TME-related PRS showed shorter OS than 206 those with low TP-related PRS (P < 0.0001) (Figure 3F). Our TP-TME risk subtype 207 was generated based the two PRSs, and 34, 52, and 123 patients with HCC were 208 divided into high-, intermediate-, and low-risk subtypes, respectively. Cases defined 209 as high-risk subtype had the best poor survival while those in low-risk subtype had the best survival, and the intermediate-risk cases had a better prognosis than high-risk 210 211 subtype and worse than low-risk subtype (Figure 3G). A similar trend was also 212 observed in progression free survival (PFS) (Figure 3H). Furthermore, the TP-TME

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- risk subtyping system showed independent to some routine clinicopathological 213
- features (Figure 3I). As it was in the GSE14520 GPL3921 data set, the TP-related 214
- 215 PRS and the TME-related PRS in the TCGA-LIHC and LIRI-JP data sets were
- 216 calculated according to the abovementioned formula, respectively. We found similar
- 217 results in the two validation sets. Briefly, the TP-related PRS (Figure 4A for
- TCGA-LIHC and Figure 5A for LIRI-JP) and the TME-related PRS (Figure 4B for 218
- TCGA-LIHC and Figure 5B for LIRI-JP) were significantly associated with OS, the 219
- TP-TME risk subtyping system was associated with OS (Figure 4C for TCGA-LIHC 220
- 221 and Figure 5C for LIRI-JP) and PFS (Figure 4D for TCGA-LIHC). The prognostic
- 222 value of the TP-TME risk subtyping system was independent to the routine
- 223 clinicopathological features (Figure 4E for TCGA-LIHC and Figure 5D for LIRI-JP).
- 224 Collectively, the TP-TME risk subtyping is a robust prognosis prediction system.

225 The subtype-specific curated gene sets of the TP-TME risk subtypes

- Compared to the TP-TME intermediate- and high-risk subtypes, the liver 226
- 227 function-related hallmark (Figure 6A) and metabolism-related Kvoto Encyclopedia of
- 228 Genes and Genomes (KEGG) (Figure 6D) gene sets were significantly enriched in
- 229 the TP-TME low-risk subtype. This suggests the TP-TME low-risk subtype HCC
- 230 were well-differentiated. The TP-TME intermediate-risk subtype was charactered by
- 231 enriching transcription factor *E2F* and *MYC* targets (Figure 6B) and cell cycle
- 232 pathways (Figure 6E), while the TP-TME high-risk subtype was charactered by
- 233 enriching hypoxia and Wntβ catenin signaling (**Figure 6C**), and Notch signaling
- 234 pathway and TGF β signaling pathway (Figure 6F). These results indicated that there
- 235 is significant biological heterogeneity between these three subtypes.

236 These three TP-TME risk subtypes may respond differently to immunotherapy

- 237 The Figures 7A-C show the top 30 mutation genes in the low-, intermediate-, and
- high-risk subtypes, respectively. However, few known drugs so far targeted these 238
- 239 genes for HCC. The tumor mutational burden (TMB) in HCC was low, and no
- 240 significantly different among these three subtypes (Figure 7D). This suggests TMB
- 241 may not be an efficient biomarker for selecting patients with HCC for ICI treatment.
- In addition, our analysis also found no significant difference in the stemness score 242
- 243 among these three risk subtypes (Figure 7E). Though the CD274 (also known as
- 244 PDL1) expression of the three risk subtypes show no significantly differentially
- 245 (Figure 7F), the expressions of CTLA4 (Figure 7G) and PDCD1 (also known as PD1)
- (Figure 7H) were higher in the intermediate-risk subtypes than the low-risk subtypes. 246
- 247 Thus, the intermediate-risk subtype may possess a higher response rate to treatment
- with ICIs more than the low-risk subtype. In addition, the three TP-TME risk 248
- 249 subtypes have distinct expression levels of the five cancer antigens which were used
- 250 as targets in the chimeric antigen receptor-modified T cell (CAR-T) therapy. The

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 251 GPC3 express higher in the intermediate-risk subtype than the low-risk subtype
- 252 (Figure 7I), the MSLN express higher in the intermediate- and high-risk subtypes
- than the low-risk subtypes (Figure 7J). Impressively, the high-risk subtypes have
- highest expression of MUC1 (Figure 7K), EPCAM (Figure 7L), and PROM1
- 255 (Figure 7M). Thus, theoretically, the three TP-TME risk subtypes may respond
- 256 differently to corresponding CAR-T therapies.

257 Potentially effective drugs for the high-risk subtypes

258 Many agents which tried to treat HCC evaluated in phase 3 trials got the disappointing

results,(1) the response is usually observed in a small subset of individuals. Through

260 the PATHOME-Drug analysis, we constructed the drug-target networks to identify

the potentially effective drugs for the high-risk subtypes (**Figure 8**). The potentially

- 262 effective drugs include recommended agents such as sorafenib, regorafenib, and
- 263 cabozantinib, and some drugs which are used to treat other diseases (Supplementary
- 264 **Table 3**).

265 **DISCUSSION**

The heterogeneity of HCC is attributed to the presence of various etiologies, such as infections of virus or parasitic, chemical carcinogens, cigarette smoking, excess

- 268 alcohol intake, and dietary factors.(1) Accordingly, the host's response to various
- 269 pathogenic factors leads to the formation of their own unique microenvironment. One
- 270 hypothesis is that different TMEs and pathogenic factors may evoke distinct
- 271 molecular alteration to independently initiate HCC progress, which results in
- 272 extensive inter-tumor molecular heterogeneity. One of the essential efforts for
- 273 improving the poor outcome of HCC is to provide a subtyping system that is capable
- of accurately defining tumor risk subtypes, each displaying unique molecular
- characteristics linked to potentially druggable driver genes in order to provide
- 276 personalized treatment choices based on the subtyping system. Though many efforts,
- 277 mainly focusing on the malignant cells, were paid to elaborate the inter-tumor
- heterogeneity and propose various single- or multi-omics-based molecular typing
- systems, (5, 29) their effectiveness remain limited for providing precision treatment. In
- this scope, given that the crucial role of TME in cancers is confirmed,(30)
- 281 TME-related molecules should be contributed to the subtyping for HCC. Another
- 282 challenge of previous molecular typing methods is cost effectiveness, due to they
- 283 need hundreds of genes or even multiple omics data types.
- In our present study, we firstly identified the related genes of TP and TME and
- subsequently generated a TP-related PRS and a TME-related PRS according to the
- 286 expression patterns of these types of genes, and furtherly proposed a novel risk
- subtyping that could successfully divide patients with HCC into three risk subtypes.

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- Similar to other molecular typing systems,(31-34) our subtypes have distinct
 prognosis and were validated in two independent external data sets. As reviewed by
 Wu et al.(5) a few subtypes were repeatedly uncovered in different studies, indicating
- wu et al.(5) a few subtypes were repeatedly uncovered in different studies, indicatin
- that different HCC subtypes derived from different omics technologies may share
 common molecular characteristics. Our TP-TME low-risk subtype may be
- well-differentiated and enrich gene sets related to liver function (e.g., bile acid
- 294 metabolism), similar to the Hoshida's S3 subtype(35) and TCGA's ICluster2. The
- 295 TP-TME intermediated-risk subtype exhibited activated MYC targets and
- 296 proliferation-related gene sets (e.g., cell cycle and G2M checkpoint), corresponding to
- the Hoshida's S2 subtype and Chaisaingmongkol et al.'s C1 subtype.(36) The
- 298 TP-TME high-risk subtype characterized by aberrant activation of TGF β and WNT
- 299 pathways, displayed multiple similarities with Hoshida's S1 subtype and Kurebayashi
- 300 et al.'s immune-high subtype.(37) Compared with these typing methods, low cost is
- 301 the potential advantage of our TP-TME risk subtyping system. In addition, though the
- 302 further study was required, we also proposed the potential immunotherapy and drugs
- 303 for the high-risk subtype, which may help for decision-making in clinical practice.
- 304 Unsurprisingly, some of these the candidate eleven TP-related and seven TME-related
- 305 genes have been found to be associated with HCC or other types of cancers in
- 306 previous studies. *ESM1* was found as a biomarker of macrotrabecular-massive
- 307 HCC.(38) HEY1 plays a critical role in hypoxia-related regulation of mitochondrial
- activity in HCC.(39) *RCN2* can enhance HCC proliferation via modulating the
- 309 EGFR-ERK pathway.(40) The interactions between CTSC and TNF- α /p38 MAPK
- 310 signaling pathway are associated with proliferation and metastasis in HCC.(41)
- 311 LANCL1 was reported that can protect prostate cancer cells from oxidative stress.(42)
- 312 XPO1-dependent nuclear export was proposed as a target for cancer therapy.(43)
- 313 However, the associations of some TP-related or TME-related genes and HCC have
- been not noted in the previous study. According to our current analysis, we provide
- 315 potential candidate molecules for further research on HCC.
- 316 Although our current study provided a novel molecular classification system, it has
- 317 some noted limitations. Firstly, the roles of some candidate genes in HCC remain
- 318 elusive, it is not clear whether these genes are causal or merely prognostic markers for
- 319 HCC. Secondly, the TP-TME risk subtyping system was generated from a
- 320 retrospective analysis, it should be validated or improved by the prospective trials
- 321 before being used in clinical practice.

322 CONCLUSIONS

323 In conclusion, by combining separately constructed TP-related PRS and TME-related 324 PRS, we proposed and validated a novel molecular classification system, the TP-TME

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 325 risk subtyping system, to divide patients into three subtypes with distinct biological
- 326 characteristics and prognosis. These findings highlight the significant clinical
- 327 implications of the TP-TME risk subtyping system and provide potential personalized
- 328 immunotherapy strategies for patients with HCC.

329 ACKNOWLEDGMENTS

330 Not available

331 **COMPETING INTERESTS**

332 The authors declare that they have no competing interests.

333 FUNDING

- 334 This research was supported by the National Natural Science Foundation of China
- 335 (NO. 81803007, 82060427, 82103297), Guangxi Key Research and Development
- 336 Plan (NO. GUIKEAB19245002), Guangxi Scholarship Fund of Guangxi Education
- 337 Department, Guangxi Natural Science Foundation (NO. 2020GXNSFAA259080),
- 338 Guangxi Medical University Training Program for Distinguished Young Scholars,
- 339 Science and Technology Plan Project of Qingxiu District, Nanning (NO. 2020037,
- 340 2020038).

341 AUTHORS CONTRIBUTIONS

- 342 YJZ, LXL, and WGB designed the study and revised the manuscript. LY and LR
- 343 performed the analyses and wrote the manuscript. GX, HZQ, LL, LM, LQ, WXB, and
- 344 LYQ assisted with analyzing the data and writing the manuscript. All authors read and
- 345 approved the final manuscript.

346 DATA AVAILABILITY

- 347 The datasets used during the current study are available in the HCCDB repository,
- 348 [http://lifeome.net/database/hccdb/home.html]

349 CODE AVAILABILITY

The code used during the current study is available from the corresponding author upon request.

352 ETHICS APPROVAL

Not available.

Novel Molecular Classification of HCC

354 **CONSENT TO PARTICIPATE**

355 Informed consent was obtained from all individual participants included in the study.

356 **CONSENT TO PUBLISH**

357 Not available.

358 REFERENCES

- 359 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 1. 360 2018;391(10127):1301-14.
- 361 2. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65(5):1031-42. 362
- 363 3. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC 364 TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 365 366 2007;245(6):909-22.
- 367 4. Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, et al. Clinical 368 Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology. 2020;71(1):164-82. 369
- 370 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step 5. 371 toward precision medicine. Cancer Commun (Lond). 2020;40(12):681-93.
- Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, et al. 372 6. 373 Molecular predictors of prevention of recurrence in HCC with sorafenib as 374 adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68(6):1065-75. 375
- 376 Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to 7. 377 the tumor microenvironment. Cancer Cell. 2012;21(3):309-22.
- Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting 378 8. the tumor microenvironment: removing obstruction to anticancer immune 379 380 responses and immunotherapy. Ann Oncol. 2016;27(8):1482-92.
- Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, et al. HCCDB: A Database of 381 9. 382 Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics. 2018;16(4):269-75. 383

| 384 385 386 | 10. | Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202-12. |
|--------------------------|-----|--|
| 387 388 389 | 11. | Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. |
| 390 391 | 12. | Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. |
| 392 393 394 | 13. | Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. |
| 395 396 397 398 | 14. | Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D13. |
| 399 400 401 | 15. | Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504. |
| 402 403 | 16. | Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. 2010. 2010;33(1):22. |
| 404 405 406 | 17. | Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267-73. |
| 407 408 409 410 | 18. | Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50. |
| 411 412 413 | 19. | Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-40. |
| 414 415 416 | 20. | Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417-25. |

| 417 418 419 | 21. | Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. |
|--------------------------|-----|---|
| 420 421 | 22. | Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812-30 e14. |
| 422 423 424 | 23. | Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018;173(2):338-54 e15. |
| 425 426 427 | 24. | Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38(1):268. |
| 428 429 430 | 25. | Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, et al. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel). 2020;12(10). |
| 431 432 433 434 | 26. | Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53(2):141-56. |
| 435 436 | 27. | Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019;15(12):2548-60. |
| 437 438 439 | 28. | Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381-97. |
| 440 441 | 29. | Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer. 2016;5(2):128-38. |
| 442 443 | 30. | Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79(18):4557-66. |
| 444 445 446 | 31. | Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169(7):1327-41 e23. |

| 447 448 449 | 32. | Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48(5):500-9. |
|--------------------------|-----|---|
| 450 451 452 | 33. | Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667-76. |
| 453 454 455 | 34. | Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257-61. |
| 456 457 458 | 35. | Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385-92. |
| 459 460 461 | 36. | Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, et al. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell. 2017;32(1):57-70 e3. |
| 462 463 464 465 | 37. | Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025-41. |
| 466 467 468 | 38. | Calderaro J, Meunier L, Nguyen CT, Boubaya M, Caruso S, Luciani A, et al. ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(19):5859-65. |
| 469 470 471 | 39. | Kung-Chun Chiu D, Pui-Wah Tse A, Law CT, Ming-Jing Xu I, Lee D, Chen M, et al. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death Dis. 2019;10(12):934. |
| 472 473 474 | 40. | Ding D, Huang H, Jiang W, Yu W, Zhu H, Liu J, et al. Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway. Oncogene. 2017;36(48):6691-700. |
| 475 476 477 | 41. | Zhang GP, Yue X, Li SQ. Cathepsin C Interacts with TNF-alpha/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res Treat. 2020;52(1):10-23. |

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 478 42. Wang J, Xiao Q, Chen X, Tong S, Sun J, Lv R, et al. LanCL1 protects prostate
 479 cancer cells from oxidative stress via suppression of JNK pathway. Cell Death Dis.
 480 2018;9(2):197.
- 43. Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy.
 482 J Hematol Oncol. 2020;13(1):61.
- 483

484 Figure legends

- 485 **Figure 1 The workflow of the present study.**
- 486 Abbreviation: LASSO, least absolute shrinkage and selection operator; TP, tumor
- 487 purity; TME, tumor microenvironment; TCGA-LIHC, The Cancer Genome
- 488 Atlas-liver hepatocellular carcinoma; ICGC-LIRI-JP: Liver Cancer-RIKEN, JP.

Figure 2 The identification, enrichment analysis, and protein-protein interaction networks of the tumor purity-related genes and tumor

- 491 microenvironment-related genes. (A) The volcano plot of the differentially
- 492 expressed gene analysis; (B) Hierarchical clustering showed the expression patterns of
- 493 tumor purity (TP)-related and tumor microenvironment (TME)-related genes basically
- 494 distinguish hepatocellular carcinoma (HCC) and tumor-adjacent liver tissues. (C)
- 495 Functional enrichment analysis for the TP-related genes. Left panel: GO terms and
- 496 pathways involving TP-related genes, and *right panel*: interactions among the GO
- 497 terms and pathways. (**D**) Functional enrichment analysis for the TME-related genes.
- 498 *Left panel:* GO terms and pathways involving TME-related genes, and *right panel*:
- 499 interactions among the GO terms and pathways. (E) protein-protein interaction
- 500 networks of the TP-related genes and TME-related genes. The red represents
- 501 up-regulated, and the blue represents down-regulated in hepatocellular carcinoma.
- 502 The circle nodes were TP-related genes, and the diamond nodes were TME-related
- 503 genes.
- 504 Abbreviation: TME, tumor microenvironment; TP, tumor purity; HCC,
- 505 hepatocellular carcinoma; GO, gene ontology.

506 Figure 3 The development of TP-TME risk subtypes in GSE14520_GPL3921

- 507 data set. (A) twenty-two TP-related genes had non-zero coefficients in the LASSO
- 508 Cox regression model analysis; (**B**) Time-dependent ROC curve analysis for the
- 509 TP-related PRS; (C) HCC with high TP-related PRS had shorter overall survival than
- 510 those with low TP-related PRS. (D) Ten TME-related genes had non-zero coefficients
- 511 in the LASSO Cox regression model analysis; (E) Time-dependent ROC curve
- analysis for the TME-related polygenic risk score; (**F**) HCC with high TME-related
- 513 PRS had shorter overall survival than those with low TME-related PRS. (G) There are

perpetuity. All rights reserved. No reuse allowed without permission.

Novel Molecular Classification of HCC

- 514 significantly different overall survivals between the three subtypes in the TP-TME
- 515 risk subtypes. (H) There are significantly different progression free survivals between
- 516 the three subtypes in the TP-TME risk subtypes. (I) The TP-TME risk subtype system
- 517 was proved to be an independent prognostic factor, after adjusting for other
- 518 clinicopathological characteristics.
- 519 Abbreviation: LASSO, least absolute shrinkage and selection operator; TP, tumor
- 520 purity; TME, tumor microenvironment; HCC, hepatocellular carcinoma; ROC,
- 521 receiver operating characteristic; PRS, polygenic risk score.

522 Figure 4 The validation of TP-TME risk subtypes in TCGA-LIHC data set. (A)

- 523 HCC with high TP-related PRS had shorter overall survival than those with low
- 524 TP-related PRS. (**B**) HCC with high TME-related PRS had shorter overall survival
- 525 than those with low TME-related PRS. (C) There are significantly different overall
- 526 survivals between the three subtypes in the TP-TME risk subtypes. (**D**) There are
- 527 significantly different progression free survivals between the three subtypes in the
- 528 TP-TME risk subtypes. (E) The TP-TME risk subtype system was proved to be an
- independent prognostic factor, after adjusting for other clinicopathologicalcharacteristics.
- 530 characteristics.
- Abbreviation: TP, tumor purity; TME, tumor microenvironment; PRS, polygenic
 risk score; AFP, alpha fetoprotein.

533 Figure 5 The validation of TP-TME risk subtypes in LIRI-JP data set. (A) HCC

sith high TP-related PRS had shorter overall survival than those with low TP-related

- 535 PRS. (**B**) HCC with high TME-related PRS had shorter overall survival than those
- 536 with low TME-related PRS. (C) There are significantly different overall survivals
- between the three subtypes in the TP-TME risk subtypes. (**D**) The TP-TME risk
- 538 subtype system was proved to be an independent prognostic factor, after adjusting for
- 539 other clinicopathological characteristics.
- 540 Abbreviation: TP, tumor purity; TME, tumor microenvironment; PRS, polygenic
- 541 risk score; NBNC, no hepatitis B virus and no hepatitis C virus; HBV, hepatitis B
- 542 virus; HCV, hepatitis C virus; AJCC, American Joint Committee on Cancer.
- 543 Figure 6 Gene set enrichment analysis for identifying the subtype-specific
- 544 curated gene sets of the TP-TME risk subtypes. The hallmark gene sets enriched in
- 545 the (A) TP-TME low-risk subtype, (B) TP-TME intermediate-risk subtype, and (C)
- 546 TP-TME high-risk subtype. The Kyoto Encyclopedia of Genes and Genomes (KEGG)
- 547 pathway gene sets enriched in the (**D**) TP-TME low-risk subtype, (**E**) TP-TME
- 548 intermediate-risk subtype, and (F) TP-TME high-risk subtype.

549 Figure 7 Mutation, stemness, and immunotherapeutic efficacy analysis. Top 30

550 mutant genes in the (A) TP-TME low-risk subtype, (B) TP-TME intermediate-risk

- 551 subtype, (C) and TP-TME high-risk subtype. (D) Tumor mutation burden in the three
- 552 TP-TME high-risk subtypes. (E) Stemness score in the three TP-TME high-risk
- 553 subtypes. The expression of (F) CD274, (G) CTLA4, (H) PDCD1, (I) GPC3, (J)
- 554 MSLN, (K) MUC1, (L) EPCAM, and (M) PROM1 in the three TP-TME high-risk
- 555 subtypes.
- Figure 8 Drug-target networks for potentially effective drugs for the TP-TME 556
- high-risk subtypes. The red represents up-regulated, and the blue represents 557
- down-regulated in the TP-TME high-risk subtypes. 558
- 559 Supplementary Table 1 The overall survival-associated tumor purity-related 560 genes in hepatocellular carcinoma
- 561 Supplementary Table 2 The overall survival-associated tumor
- 562 microenvironment-related genes in hepatocellular carcinoma
- 563 Supplementary Table 3 Potentially effective drugs and relevant targets for the
- 564 high-risk subtypes









Cell Cycle Metabolism of RNA ribonucleoprotein complex biogenesis mitotic cell cycle process DNA repair S Phase Regulation of TP53 Activity through Phosphorylation tRNA processing regulation of cell cycle process DNA mismatch repair positive regulation of DNA metabolic process DNA IR-damage and cellular response via ATR ribosome biogenesis Gastric cancer network 1 regulation of protein catabolic process protein-DNA complex subunit organization Cholesterol biosynthesis pathway covalent chromatin modification G2/M Transition response to radiation

D



R-HSA-9031628: NGF-stimulated transcription GO:0009617: response to bacterium GO:0010035: response to inorganic substance GO:0010942: positive regulation of cell death GO:0034612: response to tumor necrosis factor GO:0030854: positive regulation of granulocyte differentiation GO:2000107: negative regulation of leukocyte apoptotic process R-HSA-1280215: Cytokine Signaling in Immune system GO:0070848: response to growth factor GO:0002252: immune effector process GO:0009612: response to mechanical stimulus GO:0030198: extracellular matrix organization GO:0006909: phagocytosis GO:0030162: regulation of proteolysis GO:0000302: response to reactive oxygen species GO:0019221: cytokine-mediated signaling pathway ko04668: TNF signaling pathway GO:0043491: protein kinase B signaling GO:0046718: viral entry into host cell GO:0007507: heart development

В



NGF-stimulated transcription response to bacterium response to inorganic substance positive regulation of cell death response to tumor necrosis factor positive regulation of granulocyte differentiation negative regulation of leukocyte apoptotic process Cytokine Signaling in Immune system response to growth factor immune effector process response to mechanical stimulus extracellular matrix organization phagocytosis regulation of proteolysis response to reactive oxygen species cytokine-mediated signaling pathway TNF signaling pathway protein kinase B signaling viral entry into host cell heart development

| DPF2 | AATF | PTGDS | STMN1 | PARP2 | PEG10 | MRC1 | ACTL6A | VPS54 | RPP40 | CD46 | RNASEH2A | COPE | RAD1 | DUSP12 | STT3A | CAND1 | SPAG5 |
|---------------|--|---|--|--|---|--------|----------|---------|---------|---------|----------|---------|-------|---------|---------|--------|----------|
| PPM1G | DYNLRB1 | HMMR | ZNF207 | TPR | ELAVL1 | RPA2 | MSH6 | SLC39A1 | SAC3D1 | IRF8 | USP39 | XPO1 | GBP1 | PSMD8 | MRGBP | MFF | IL7R |
| SNF8 | TUBG1 | MRPL42 | KIF15 | RACGAP1 | KDELR2 | NUP205 | MIF | P4HA2 | PRC1 | IER2 | PWP1 | E2F6 | EFNA1 | TXNIP | HEY1 | MRPS10 | CDK5 |
| MT1E medR pre | xiv preprint doi: https://doi print (which was not certif PIGF | i.org/10.1101/2022.02.13.2 fied by peer review) is the a | 2270882; this version post author/funder, who has gra perpetuity No reuse allowed without | ted February 15, 2022. T anted medRxiv a license permis <mark>sign.E1</mark> | the copyright holder for this to display the preprint in FDPS | s GGT5 | RFC2 | MAPK6 | TRRAP | PSMD4 | SGCE | TRIM24 | GGT1 | UFC1 | CDCA3 | NSDHL | USP14 |
| MRPS16 | ZNHIT3 | AHCTF1 | HSPA14 | COIL | RUVBL2 | RAD51C | PPP1CC | NUP155 | AXL | GORASP2 | MRPL24 | PDZK1 | SLBP | CASK | GSN | UBE2N | AURKB |
| CSNK2A1 | CSNK2B | POGK | UBE2S | TPX2 | GMNN | SNRPB | EVI2B | STAMBP | TP53BP2 | MARK4 | MIS18A | UBAP2L | LY96 | CANX | DHODH | SRP9 | ARF1 |
| PCNA | LIG1 | TCEA1 | ISG20L2 | NIPA2 | UTP6 | RRP15 | FCGR2B | PSMD1 | EGR1 | DSN1 | ХРОТ | VPS72 | CEBPG | LRPPRC | PTGES3 | HS2ST1 | COPS6 |
| GINS2 | NUP133 | SNRPD1 | SLC39A6 | NVL | FYN | CSNK1D | RPRD2 | POLE2 | UCHL5 | GINS1 | ILF3 | NABP2 | SMG8 | DHCR7 | SMARCC1 | UBE2M | PIGC |
| TAF6 | CCT2 | REPIN1 | SCAMP3 | HSP90AB1 | HSPE1 | FIBP | CRNKL1 | MOB4 | FLAD1 | TOMM20 | ССТ7 | TMCO1 | CKAP5 | KIF14 | ITGA6 | ACACA | BUD31 |
| GSTA4 | SLC35E3 | FOS | COL15A1 | ZC3H15 | NEK4 | POLR3C | ADNP | DONSON | CHEK2 | CYFIP2 | CACYBP | CHD1L | CD1D | SLC26A6 | SNRPF | PUS7 | AHSA1 |
| CDK4 | SNRPC | SDC3 | TRIM28 | ORC3 | BARD1 | ID4 | MTIF2 | SLC29A1 | GEMIN6 | EGLN1 | HCLS1 | SLC50A1 | SF3B4 | SEH1L | POP5 | IARS2 | PAIP1 |
| GGPS1 | GTF2A2 TM | MEM189-UBE2 | /1 STIP1 | GAS6 | FOSB | ССТЗ | ITGB3BP | EIF2D | GGCT | LSM4 | EDEM3 | SSR2 | WDR12 | HEATR1 | AURKA | PRPF4B | MNS1 |
| КОМЗА | PARP1 | NUP107 | HMGCR | CYP51A1 | LRIF1 | CBX1 | RFC5 | ZWILCH | SPDL1 | TACC2 | TRIM22 | MCM7 | RUSC1 | RRM1 | ALG6 | SPRY2 | BSG |
| MCM4 | NECAB3 | KDM5B | NEK2 | BMI1 | PIGT | RGL1 | FANCF | TAF9 | GNB5 | ESF1 | C17orf75 | CDKN3 | UTP18 | TMEM258 | THOC2 | PLOD3 | PAXIP1 |
| CASD1 | CAD | RPRD1A | ILF2 | CUTA | STAT4 | CENPF | PFDN2 | COMMD4 | TRMT61B | FANCI | ALG3 | NCOA6 | RMI1 | CH25H | TRIB1 | NUP37 | ATP6V1C2 |
| EIF6 | HGS | MT1H | C4A | TSC22D3 | UBE2Q1 | COL4A2 | MAPK9 | SNRPB2 | DARS2 | FAS | SAP130 | DTL | CKS1B | TRMT112 | MYO5C | BANF1 | ACTR6 |
| PPM1D | E2F8 | EIF3B | BAG2 | LIN37 | ZFP36 | IPO9 | ANP32E | SMG5 | CYP1A2 | MFAP1 | DNAJC9 | RPS21 | OIP5 | JUNB | HLTF | RBCK1 | GTF3C3 |
| SUZ12 | MDC1 | PSMD11 | TDP2 | HSPA1B | MTX1 | RFC3 | TNFRSF1B | РВК | AGAP1 | SNRPE | SUPT16H | SQLE | MRPL9 | COG2 | NCSTN | CD69 | MRPL11 |
| NCAPG2 | RALBP1 | FTSJ3 | POP7 | PRIM1 | ARPC1A | NEDD4L | RBM42 | ABCF1 | MSH2 | EGR2 | YEATS4 | PRKDC | FANCG | UNG | GLB1 | BIRC3 | NEU1 |



Months

| | MALE (N=183) | 1.70 (0.753 - 3.85) | | | | | | | | 0.201 |
|---|--------------------------------------|-------------------------|-----|---------------|-----|------------------|---------|---|----|--------------|
| Age | (N=209) | 1.01 (0.984 - 1.03) | | | | | | | | 0.506 |
| Main_Tumor_Size | =<5cm (N=133) | reference | | | | | | | | |
| | >5cm (N=76) | 0.71 (0.410 - 1.24) | | | | н і н | | | | 0.235 |
| Multinodular | N (N=169) | reference | | | | | | | | |
| | Y (N=40) | 0.48 (0.254 - 0.89) | | ب ــــ | - | | | | | 0.021 * |
| Cirrhosis | N (N=16) | reference | | | | | | | | |
| | Y (N=193) | 2.09 (0.499 - 8.74) | | | | | - | | | 0.313 |
| AFP | <=300ng/ml (N=115) | reference | | | | | | | | |
| | >300ng/ml (N=94) | 1.13 (0.699 - 1.84) | | | F | - | | | | 0.612 |
| TNM.staging | l (N=90) | reference | | | | | | | | |
| | ll (N=74) | 1.98 (1.095 - 3.60) | | | | ļ | - | | | 0.024 * |
| | III (N=43) | 5.56 (2.573 - 12.00) | | | | | | - | | <0.001 *** |
| | Unknown (N=2) | 0.77 (0.095 - 6.32) | ı | | - | | | | | 0.812 |
| TP-TME risk subtype | Low (N=123) | reference | | | | | | | | |
| | Intermediate (N=52) | 2.92 (1.633 - 5.22) | | | | | | a | | <0.001 *** |
| | High (N=34) | 8.02 (4.299 - 14.97) | | | | | | | - | ┩ <0.001 *** |
| # Events: 79; Global p-valu AIC: 727.46; Concordance | ie (Log-Rank): 7.1607 Index: 0.77 | ′e−14 | 0.1 | 0.2 | 0.5 | 1 | 2 | 5 | 10 | 20 |





medRxiv preprint doi: https://doi.org/10.110/2922.02.13.22270882; this version posted February 19,2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funtee who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



TP-TME risk subtype 📥 High 📥 Intermediate 📥 Low



Survival probability

D





| GENDER | FEMALE (N=104) | reference | | | | | | |
|---|-------------------------|-------------------------|------------|-----|---|----|----|----------|
| | MALE (N=225) | (0.79 (0.49 - 1.3) | · | | | | | 0.35 |
| AGE | (N=329) | (0.99 - 1.0) | | | | | | 0.546 |
| Grade | G1 (N=50) | reference | | | | | | |
| | G2 (N=155) | 1.47 (0.56 - 3.9) | | - | | | | 0.431 |
| | G3 (N=108) | 1.33 (0.49 - 3.6) | | | | | | 0.582 |
| | G4 (N=11) | 5.48 (1.30 - 23.0) | | | | | | 0.02 * |
| | Unknown (N=5) | reference | | | | | | |
| Child_Pugh | A (N=197) | reference | | | | | | |
| | B (N=20) | (0.87 - 4.7) | | - | | | | 0.102 |
| | C (N=1) | 6.81 (0.83 - 55.6) | | | | | | 0.074 |
| | Unknown (N=111) | 1.45 (0.79 - 2.7) | . <u> </u> | | | | | 0.231 |
| AFP | <=300ng/ml (N=188) | reference | | | | | | |
| | >300ng/ml (N=60) | 0.82 (0.44 - 1.5) | - | | | | | 0.538 |
| | Unknown (N=81) | 1.97 (1.04 - 3.7) | | | | | | 0.037 * |
| AJCC_STAGE | Stage I (N=154) | reference | | | | | | |
| | Stage II (N=73) | 1.19 (0.57 - 2.5) | | | | | | 0.641 |
| | Stage III (N=78) | 2.39 (1.31 - 4.4) | | | | | | 0.005 ** |
| | Stage IV (N=3) | 4.86 (1.18 - 19.9) | | · | - | | | 0.028 * |
| VASCULAR_INVASION | None (N=178) | reference | | | | | | |
| | Macro (N=16) | (0.53 - 3.3) | | | - | | | 0.543 |
| | Micro (N=81) | (0.57 - 2.0) | . | | | | | 0.843 |
| TP-TME risk subtype | Low (N=95) | reference | | | | | | |
| | Intermediate (N=190) | (0.91 ⁻ 3.2) | - | | - | | | 0.099 |
| | High (N=44) | 4.19 (1.73 - 10.1) | | | | | | 0.001 ** |
| # Events: 78; Global p-value (Log-F AIC: 736.8; Concordance Index: 0.7 | Rank): 9.3909e-05 1 | | | | | | | |
| | | | 0.5 | 1 2 | 5 | 10 | 20 | 50 10 |

Е

4000

Hazard ratio



D



Hazard ratio

| | GENDER | Male (N=160) | reference | | ļ |
|-----------------------|--|---|-------------------------|---|---|
| | | Female (N=50) | 4.09 (1.75 - 9.6) | | |
| medRxiv preprint doi: | AGE https://doi.org/10.1101/2022.02.13.22270882; this version posted February 1 | (N=210) 5, 2022. The copyright holder for this | 1.02 (0.97 - 1.1) | | |
| proprint (which wa | All rights reserved. No reuse allowed without permission. | NBNC (N=32) | reference | | |
| | | HBV (N=52) | 3.15 (0.67 - 14.8) | | - |
| | | HBV, HCV (N=4) | 13.14 (1.92 - 89.7) | | |
| | | HCV (N=122) | 2.83 (0.80 - 10.0) | | F |
| | AJCC_STAGE | l (N=33) | reference | | |
| | | ll (N=102) | 3.34 (0.68 - 16.4) | | Ļ |
| | | III (N=59) | 9.87 (1.80 - 54.2) | | |
| | | IV (N=16) | 35.88 (5.34 - 240.9) | | |
| | VASCULAR_INVASION | Negative (N=145) | reference | | |
| | | Positive (N=65) | 0.43 (0.17 - 1.1) | - | |
| | TP-TME risk subtype | Low (N=113) | reference | | |
| | | Intermediate (N=70) | 4.53 (1.83 - 11.2) | | |
| | | High (N=27) | 7.24 (2.68 - 19.6) | | |
| _ | # Events: 34; Global p-value AIC: 302.46; Concordance Inc | (Log-Rank): 2.4364e dex: 0.82 | -06 | | |

0.2 0.5





Low risk-----Intermediate and High risk

Intermediate risk-----Low and High risk

High risk-----Low and Intermediate risk

Α

1250



Altered in 141 (89.81%) of 157 samples.

